Dr Reddy wins $525,000 grant for anti-prostate cancer therapeutic agent
Morehouse School of Medicine (MSM) will be able to continue its revolutionary research on prostate cancer—a disease that killed more than 27,000 men in the United States in 2006—thanks to a new grant by the U.S. Department of Defense (DOD).
Nothing great can be achieved without a passion, says Dr. Reddy, Georgia Cancer Coalition (GCC) Distinguished Cancer Scholar, professor and co-director, Cancer Biology Program, MSM Department of Obstetrics and Gynecology at the Georgia Cancer Center for Excellence at Grady Health System.
Prostate cancer is the most common non-skin cancer and the second leading cause of cancer death in men in the United States. One in six men in the U.S. will receive the diagnosis in his lifetime. The gene discovered by Reddy and Veena N. Rao, Ph.D., co-director of the Cancer Biology Program, is involved in 60 to 80 percent of prostate cancers. Reddy identified a novel targeted therapeutic agent that inhibits ERG function and also functions as an anti-cancerous agent against prostate cancer. This award gives an opportunity to further the study and test the drug in preclinical trials. It will also help to reduce health disparities seen among minorities, which supports the mission of Morehouse School of Medicine, says Reddy.
Enjoyed reading Khabar magazine? Subscribe to Khabar and get a full digital copy of this Indian-American community magazine.
